Application of Saliva for Drug Monitoring an in Vivo Model for Transmembrane Transport

Clinical Chemistry and Laboratory Medicine

Volumn 34, Issue 3, 1996, Pages 171-192

  Haeckel, Rainer ^a   Petra, Hänecke ^a  

^a Zentralkrankenhaus St Jürgen Stra e   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANALGESIC AGENT; ANESTHETIC AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CEFTAZIDIME; DIGOXIN; METHOTREXATE; PRILOCAINE; SEDATIVE AGENT; UNINDEXED DRUG;

ACTIVE TRANSPORT; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SALIVA LEVEL; DRUG TRANSPORT; HUMAN; IONIZATION; LABORATORY TEST; MEMBRANE TRANSPORT; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SALIVA ANALYSIS;

ANESTHETICS, LOCAL; ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; CELL MEMBRANE PERMEABILITY; DIGOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; ENZYME INHIBITORS; HUMANS; HYDROGEN-ION CONCENTRATION; PROTEIN BINDING; SALIVA; STREET DRUGS;

EID: 0029932091     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm.1996.34.3.171     Document Type: Article

References (179)

1. Bochner F, Hooper WD, Sutherland JM, Eadie MJ, Tyrer JH. Diphenylhyadantoin concentrating in saliva. Arch Neurol 1974; 31: 57-59.
2. Cook CE, Amerson E, Poole WK, Lesser Ph, O'Tuama L. Phenytoin and phenobarbital concentrations in saliva and plasma measured by radioimmunoassay. Clin Pharmacol Therap 1975; 18: 742-747.
3. Reynolds F, Ziroyanis PN, Jones NF, Smith SE. Salivary phenytoin concentrations in epilepsy and in chronic renal failure. Lancet 1976; 2: 384-386.
4. Brügmann G, Kleinau E, Nolle R, Petruch F. Comparison of phenytoin determination in plasma, plasma dialysate and saliva for control of antiepileptic therapy in children. Klin Wochenschr 1979; 57: 93-94.
5. Anavekar SA, Saunders RH, Wardell WM, Shoulson I, Emmings FG, Cook CE, Gringer AJ. Parotid and whole saliva in the prediction of serum total and free phenytoin concentrations. Clin Pharmacol Therap 1978; 24: 629-637.
6. Bachmann K, Forney RB, Voeller K. Monitoring phenytoin in salivary and plasma ultrailItrates of pediatric patients. Ther Drug Monit 1983; 5: 325-329.
7. KJlpatrick CJ, Wanwimolruk S, Wing LMH. Plasma concentrations of unbound phenytoin in the management of epilepsy. Br J Clin Pharmacol 1984; 17: 539-546.
8. Lifshitz M, Ben-Zvi Z, Gorodischer R. Monitoring phenytoin therapy using citric acid-stimulated saliva in infants and children. Ther Drug Monit 1990; 12: 334-338.
9. Chai WM, Zhu GZ, Chen G. Free phenytoin monitoring in serum and saliva of epileptic patients in China. Ther Drug Monit 1993; 15: 31-43.
10. Troupin AS, Friel P. Anticonvulsant level in saliva, serum and cerebrospinal fluid. Epilepsia 1975; 16: 223-227.
11. Callaghan N, Goggin T. A comparison of plasma and saliva levels of carbamazepine and phenytoin as monotherapy. Ir J MedSci 1984; 153: 170-173.
12. Danhof M, Breimer DD. Therapeutic drug monitoring in saliva. Clin Pharmacokinet 1978; 3: 39-57.
13. Mucklow JC Bending MR, Kahn GC, Dollery CT. Drug concentration in saliva. Clin Pharmacol Ther 1978; 24: 563-570.
14. Mucklow JC. The use of saliva in therapeutic drug monitoring. Ther Drug Monit 1982; 4: 229-247.
15. Haeckel R. Saliva, an alternative specimen in clinical chemistry. JIFCC 1990; 2: 208-217.
16. Haeckel R. Interpretation of salivary drug concentration. In: Kirschbaum C. Read GF, Hellhammer DH, editors. Assessment of hormones and drugs in saliva in biobehavioral research. Seattle: Hogrefe Huber Publishers, 1992: 297-311.
17. Drobitch RK, Svensson CK. Therapeutic drug monitoring in saliva. An update. Clin Pharmacokinet 1992; 23: 365-379.
18. Haeckel R. Factors influencing the saliva/plasma ratio of drugs. Ann NY Acad Sci 1993; 694: 128-142.
19. Raina S, Preston FM, Guggino WB, Agre P. Molecular cloning and characterization of an aquaporin c-DNA from salivary, lacrimal, and respiratory tissues. J Biol Chem 1995; 270: 1908-12.
20. Thaysen JH, Thorn NA, Schwartz IL. Excretion of urea, sodium, potassium, chloride and carbon dioxide in human parotid saliva. Amer J Physiol 1954; 178: 155-159.
21. Burgen ASV, Seeman P. The role of the salivary duct system in the formation of the saliva. Can J Biochem Physiol 1958; 36: 119-143.
22. Pfeifer S, Pflegel P, Borchert HH. Grundlagen der Biopharmazie. Berlin: VEB Verlag Volk und Gesundheit, 1988.
23. Hansch C, Dünn WJ. Linear relationships between lipophilic character and biological activity of drugs. J Phar Sci 1972; 61: 1-19.
24. Matin SB, Wan SH, Karam JH. Pharamacokinetics of tolbutamide: prediction by concentration in saliva. Clin Pharmacol Ther 1974; 16: 1052-8.
25. Rasmussen F. Salivary excretion of sulphonamides and barbiturates by cows and goats. Acta Pharmacol Toxicol 1964; 21: 11-19.
26. Zuidema J, van Ginneken CAM. Clearance concept in salivary drug excretion. Pharm Acta Helv 1983; 58 Part 1: 88-93.
27. Schmidt-Nielsen B. The pH in parotid and mandibular saliva. Acta Physiol Scand 1946; 11: 104-110.
28. McAuliffe J, Sherwin AL, Leppik IE, Shirley A, Payle B, Pippenger CE. Salivary levels of anticonvulsants: a practical approach to drug monitoring. Neurology 1977; 27: 409-413.
29. Dvorchik BH, Vesell ES. Pharmacokinetic interpretation of data gathered during therapeutic drug monitoring. Clin Chem 1976; 22: 868-878.
30. Kirschbaum C, Hellhammer D. Response variability of salivary cortisol under psychological stimulation. Eur J Clin Chem Clin Biochem 1989; 27: 237.
31. Knorring von L, Mörnstad H. Saliva secretion rate and saliva composition as a model to determine the effect of antidepressant drugs on cholinergic and noradrenergic transmission. Neuropsychobiology 1986; 15: 146-154.
32. Hubert W, de Jong-Meyer R. Emotional stress and saliva cortisol response. Eur J Clin Chem Clin Biochem 1989; 27: 235-237.
33. Kragh-Sorensen P, Larsen NE. Factors influencing nortriptyline steady-state kinetics: plasma and saliva levels. Clin Pharmacol Ther 1980; 28: 796-803.
34. Derendorf H, Rohdewald P, Möllmann H, Render J, Barth J, Neveling D. Pharmacokinetics of prednisolone after high doses of prednisolone hemisuccinate. Biopharm Drug Disp 1985; 6: 423-432.
35. Levy G. Clinical pharmacokinetics of salicylates: a reassessment. Br J Clin Pharmacol 1980; 10: 285S-290S.
36. Blanchard J, Harvey S, Morgan WJ. Relationship between serum and saliva theophylline levels in patients with cystic fibrosis. Ther Drug Monit 1992; 14: 48-54.
37. Lesko LJ, Tabor KJ, Johnson BF. Theophylline serum protein binding in obstructive airways disease. Clin Pharmacol Ther 1981; 29: 776-781.
38. Burgen ASV, Seeman P. The role of the salivary duct system in the formation of the saliva. Can J Biochem Physiol 1958; 36: 119-143.
39. Allen MA, Wrenn JM, Putney JW, Borzelleca JF. A study of the mechanism of transport of diphenylhydantoin in the rat submaxillary gland in vitro. J Pharmacol Exp Therap 1976; 197: 408-413.
40. Zuidema J, van Ginneken CAM: Clearance concept in salivary drug excretion. Pharm Acta Helv 1983; 58 Part 11: 136-143.
41. Paxton JW. Measurement of drugs in saliva: a review. Meth Find Exptl Clin Pharmacol 1979; 1: 11-21.
42. Amberson WR, Höber R. The permeability of mammalian salivary glands for organic non-electrolytes. J Cell Comp Physiol 1933; 2: 201-221.
43. Borzelleca JF, Cherrick HM. The excretion of drugs in saliva, antibiotics. J Oral Therap Pharmacol 1965; 2: 180-187.
44. Dawes CP, Kendall MJ. Comparison of plasma and saliva levels of metoprolol and oxprenolol. Br J Clin Pharmacol 1978; 5: 217-221.
45. Suzuki Y, Uematsu T, Mizuno A, Ninchoji T, Fuji K, Nakashima M. Analysis of the transport of valproic acid into saliva from serum. Biol Pharm Bull 1994; 17: 340-344.
46. Feller K, Le Petit G. On the distribution of drugs in saliva and blood plasma. Int J Clin Pharmacol 1977; 15: 468-469.
47. Sissons CH, Loong PC, Hancock EM, Cutress TW. Electrophoretic analysis of ureases in streptococcus salivarius and in saliva. Oral Microbiol Immiinol 1989; 4: 211-218.
48. Mangos JA, McSherry NR. Micropuncture study of urea excretion in parotid saliva of the rat. Am J Physiol 1970; 218: 1329-1332.
49. Bartels H, Günther E, Wallis S. Therapieüberwachung durch Bestimmung von Pharmakonzentrationen im Speichel. Monatsschr Kinderheilk 1983; 131: 13-16.
50. Haeckel R, Mühlenfeld HM. Reasons for intraindividual inconstancy of the digoxin saliva to serum concentration ratio. Eur J Clin Chem Clin Biochem 1989; 27: 653-658.
51. Köhler E, Sollich V, Schuster R, Thal W. Estimation of theophylline in saliva. Comparison of different sampling methods. Eur J Oral Sci 1995; 103: 38.
52. Kato K, Hillsgrove M, Weinhold L, Gorelick DA, Darwin WD, Cone EJ. Cocaine and metabolite excretion in saliva under stimulated and nonstimulated conditions. J Anal Toxicol 1993; 17: 338-341.
53. Kamali F, Thomas SH. Effect of saliva flow rate on saliva phenytoin concentrations: implications for therapeutic monitoring. Eur J Clin Pharmacol 1994; 46: 565-567.
54. Wood JH, Flora KP, Narasimhachari N, Baker AC. Dependence of salivary drug concentration on salivary flow rate. Meth Find Exptl Clin Pharmacol 1982; 4: 255-260.
55. Aufriebt Ch, Tenner W, Salzer Hö R, Khoss AE, Wurst E, Herkner K. Salivary IgA concentration is influenced by the saliva collection method. Eur J Clin Chem Clin Biochem 1992; 30: 81-83.
56. Haeckel R, Bucklitsch I. The comparability of ethanol concentrations in peripheral blood and saliva. The phenomenon of variation in saliva to blood concentration ratio. Bur J Clin Chem Clin Biochem 1990; 25: 199-204.
57. Haeckel R. Relationship between intraindividual variation of the saliva/plasma- and the arteriovenous concentration ratio as demonstrated by the administration of caffeine. Eur J Clin Chem Clin Biochem 1990; 28: 279-284.
58. Fink BR. Acute and chronic toxicity of local anaesthetics. Canad Anaest Soc J 1973; 20: 5-16.
59. Koysooko R, Ellis EF, Levy G. Relationship between theophylline concentration in plasma and saliva of man. Clin Pharmacol Ther 1974; 15: 454-460.
60. Niemann A, Oellerich M, Schumann G, Sybrecht GW. Determination of theophylline in saliva, using fluorescence polarization immunoassay (FPIA). J Clin Chem Clin Biochem 1985; 23: 725-732.
61. Uden DL, Miller KW, Strand LM, Johnson PB, Zaske DE. Saliva-serum theophylline concentrations: substantial intrapatient and interpatient variation in predicting serum concentrations. Therap Drug Monit 1981; 3: 143-150.
62. Posti J. Saliva-plasma drug concentration ratios during absorption: theoretical concentration and pharmacokinetic implication. Pharm Acta Helvet 1982; 57: 83-92.
63. Chiou WL, Lam G, Chen JL, Lee MG. Arterial-venous plasma concentration differences of six drugs in the dog and rabbit after intravenous administration. Res Commun Chem Pathol Pharmacol 1981; 32: 27-39.
64. Takagi K, Hasegawa T, Yamaki K, Suzuki, Nabeshima T. Secretion of ofloxacin into saliva in patients with respiratory tract infection. Int J Clin Pharmacol Ther Tox 1992; 30: 46-50.
65. Dagrosa E, Seeger K, Malerczyk V, Lameire N. Pharmakokinetik von Ofloxacin (HOE 280). Fortschritte antimikrobielle antineoplastische Chemotherapie 1984; 3-5:665-671.
66. Warlich R, Korting HC, Schäfer-Korting M, Mutschler E. Multiple-dose pharmacokinetics of ofloxacin in serum, saliva, and skin blister fluid of healthy volunteers. Antimicrobiol Agents Chemother 1990; 34: 78-81.
67. Bender B, Pressman RS, Tashman SG. Studies on excretion of antibiotics in human saliva, I penicillin and streptomycin. J Am Dent Ass 1953; 46: 164-170.
68. Dinter-Heidom H. Beitrag zur Pharmakokinetik von Deftazidim. Dissertation, Technische Universität Braunschweig 1994; 1-133.
69. Horn LW, Miles MV. Evaluation of the in vitro stability of digoxin in saliva. Ther Drug Monit 1994; 16: 221-223.
70. Meulenberg EPMM, Horman JA. The effect of pretreatment of saliva on steroid hormone concentrations. Eur J Clin Chem Clin Biochem 1990; 28: 923-928.
71. Ferguson DB, Botchway CA. Circadian variations in flow rate and composition of human stimulated submandibular saliva. Archs Oral Biol 1979; 24: 433-437.
72. Yamahara H, Lee VHL. Drug metabolism in the oral cavity. Adv Drug Deliv Rev 1993; 12: 25-40.
73. Nederfors T, Twetman S, Dahlhöf C. Effects of the thiazide diuretic bendroflumethazide on salivary flow rate and composition. Scand J Dent Res 1989; 97: 520-527.
74. Van der Merwe JHD, van Rooyen JM, Taljaard BPU, Offermeier J. Domperidone reduces the accumulation of paracetamol in saliva. Suid-Afrikaanse Tyds Wetenskap 1988; 84: 431.
75. Lange W, Floriddia DG, Pruyn FJ. In vitro binding of salicylates to saliva proteins. J Pharmaceut Sci 1969; 58: 771-773.
76. Weatherell JA, Robinson C, Rathbone MJ. Site-specific differences in the salivary concentrations of substances in the oral cavity-implications for the aetiology of oral disease and local drug delivery. Adv Drug Deliv Rev 1994; 13: 23-42.
77. Rassing MR. Chewing gum as a drug delivery system. Adv Drug Deliv Rev 1994; 13: 89-121.
78. Rathbone MJ, Drummond BK, TYicker IG. The oral cavity as a site for systemic drug delivery. Adv Drug Deliv Rev 1994; 13: 1-22.
79. Stricker H. Die Arzneistoffresorption im Gastrointestinaltrakt. Pharmazeut Ind 1970; 33: 157-160.
80. Spector R. Ceftriaxone transport through blood-brain-barrier. J Infec Dis 1987; 156: 209-211.
81. Akimoto Y, Nishimura H, Komiya M, Shibata T, Kaneko K, Fujii A, Tamura T. Concentrations of ampicillin and cefadroxil in human serum and mixed saliva following a single oral administration of talampicillin and cefadroxil, and relationships between serum and mixed saliva concentrations. Gen Pharmacol 1985; 16: 273-275.
82. Mahmod S, Al-Hakiem MHH, Landon J, Smith DS. Aminoglycoside antibiotics do not appear in saliva. Clin Chem 1983; 29: 988-989.
83. Killman SA, Thaysen JH. The permeability of the human parotid gland to a series of sulfonamide compounds, paraaminohippurate and inulin. Sand J Clin Lab Invest 1955; 7: 86-91.
84. Haeckel R, Peiffer U. Comparison of ethanol concentration in saliva and blood from police controlled persons. Blutalkohol 1992; 29: 342-349.
85. Robinson C, Strong M, Weatherell J, Rathbone M, Kirkham J. Site specific differences in salivary concentrations of substances in the oral cavity-implications for local drug delivery. Eur J Oral Sci 1995; 103: 38.
86. Koch HP, Ritchel WA. Synopsis der Biopharmazie und Pharmakokinetik. Landsberg, München: Ecomed Verlagsges. mbH, 1986: 1-392.
87. Halkin H, Sheiner LB, Peck CC, Melmon KJL Determination of the renal clearance of digoxin. Clin Pharmacol Ther 1975; 17: 385-394.
88. Lauterbach F. Enterale Resorption und Sekretion herzwirksamer Glykoside. Verh Dtsch Ges Inn Med 1977; 83: 33-45.
89. Lauterbach F. Intestinal secretion of organic ions and drugs. In: Kramer M, Lauterbach F, editors. Intestinal permeation. Oxford: Excerpta Medica Amsterdam, 1977: 173-194.
90. Meulenberg EPMM. Corticosteroids in plasma and saliva. Thesis Wageningen. CIP-Data Koninklijke Bibliotheek, Den Haag, 1995: 1-157.
91. Meulenberg EPMM. Corticosteroids in saliva and the influence of hormonal status. Eur J Oral Sci 1995; 103:S35.
92. Allera A, Wildt L. Glucocorticoid-recognizing and -effector sites in rat liver plasma membrane. Kinetics of cortocosterone uptake by isolated membrane vesicles-I. Binding and transport. J Steroid Biochem Molec Biol 1992; 42: 737-756.
93. Van Kalken CK, Giaccone G, van der Valk P, Kuiper CM, Hadisapatro MMN, Bosma SAA, et al. Multidrug resistance gene (P-glycoprotein) expression in the human fetus. Am J Pathol 1992; 141: 1063-1072.
94. Van Kalken CK, Broxterman HJ, Pinedo HM, Feller N, Dekkert H, Laukelina J, Giaccone G. Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br J Cancer 1993; 67: 284-289.
95. Sumner DJ, Russell AJ, Whiting B. Digoxin pharmacokinetics: multicompartmental analysis and its clinical implications. Br J Clin Pharmacol 1976; 3: 221-229.
96. Krivoy N, Rogin N, Greif Z, Ben-Aryeh H, Gutman D, Alroy G. Relationship between digoxin concentration in serum and saliva in infants. J Pediatrics 1981; 99: 810-811.
97. Wettrel G, Andersson KE. Clinical pharmacokinetics of digoxin in infants. Clin Pharmacokinet 1977; 2: 17-31.
98. Wettrel G, Andersson KE. Cardiovascular drugs II: digoxin. Ther Drug Monit 1986; 8: 129-139.
99. Joubert PH, Aucamp BN, Müller FO. Digoxin concentration in serum and saliva: relationship to ECG changes and dosage in healthy volunteers. Br J Clin Pharmacol 1976; 3: 1053-6.
100. Miller JJ, Valdes R. Approaches to minimizing interference by cross-reacting molecules in immunoassays. Clin Chem 1991; 37: 144-153.
101. Jusko WJ, Gerbracht L, Golden LH, Koup JR. Digoxin concentrations in serum and saliva. Res Commun Chem Pathol Pharmacol 1975; 10: 189-192.
102. Lequin RM, Boogaard A van den, Vermeulen J, Danhof M. Progesterone in saliva: pitfalls and consequent implications for accuracy of the determination. Clin Chem 1986; 32: 831-834.
103. Gurumurthy P, Rahman F, Narayana ASL, Raghupati Sarama G. Salivary levels of isoniazid and rifampicin in tuberculous patients. Tubercle 1990; 71: 29-33.
104. Koup JR, Jusko WJ, Goldfarb AL. pH-dependent secretion of procainamide into saliva. J Pharmaceut Sci 1975; 64: 2008-10.
105. Lynn RK, Olsen GD, Leger RM, Gordon WP, Smith RG, Gerber N. The secretion of methadone and its major metabolite in the gastric juice of humans. Comparison with blood and salivary concentrations. Drug Met Disp 1975; 4: 504-509.
106. Gerber N, Lynn RK. Excretion of methadone in semen from methadone addicts; comparison with blood levels. Life Sci 1976; 19: 792-797.
107. Swanson BN, Leger RM, Gordon WP, Lynn RK, Gerber N. Excretion of phenytoin into the semen of rabbits and man. Drug Metab Disp 1978; 6: 70-74.
108. Schramm W, Smith RH, Craig PA. Drugs of abuse in saliva: a review. J Analyt Toxicol 1992; 16: 1-9.
109. Cone EJ. Saliva testing for drugs of abuse. Ann NY Acad Sci 1993; 694: 91-137.
110. Hallstrom C, Lader, Curry SH, Diazepam and N-desmethyldiazepam concentrations in saliva, plasma, and CSF. Br J Clin Pharmacol 1980; 9: 333-339.
111. Haeckel R, Colic D. Verfahren zur Speichelgewinnung. In: Haeckel R, editor. Speicheldiagnostik. GIT Verlag Darmstadt: 1988: 1-12.
112. Arglebe C. Experience with the Salivette and some findings concerning its applicability for the determination of salivary components. J Clin Chem Clin Biochem 1989; 27: 247-248.
113. Tschöp M, Dressendorfer RA, Strasburger CJ. Reliability of saliva sampling devices for salivary testosterone assays. Exp Clin Endocrinol 1993; 101 Suppl 1: 178.
114. Lamey PJ, Nolau A. The recovery of human saliva using the Salivette system. Eur J Clin Chem Clin Biochem 1994; 32: 727-728.
115. Gorodischer R, Burtin P, Hwang P, Levine M, Koren G. Saliva versus blood sampling for therapeutic drug monitoring in children: patient and parental preferences and an economic analysis. Ther Drug Monit 1994; 16: 437-443.
116. Kirk JK, Dupuis RE, Miles MV, Gaddy GD, Miranda-Massari JR, Williams DM. Salivary theophylline monitoring: reassessment and clinical considerations. Ther Drug Monit 1994; 16: 58-66.
117. Knott C, Bateman M, Reynolds F. Do saliva concentrations predict plasma unbound theophylline concentrations? A problem reexamined. Br J Clin Pharmacol 1984; 17: 9-14.
118. Fräser HS, Mucklow JC, Murray S, Davies DS. Assessment of antipyrine kinetics and pharmacodynamics of procainamide. Br J Clin Pharmacol 1976; 3: 321-325.
119. Welch RM, De Angelis RL, Wingfield M, Farmer TW. Elimination of antipyrine from saliva as a measure of metabolism in man. Clin Pharmacol Ther 1975; 18: 249-258.
120. Vesell ES, Passanti GT, Glenwright PA, Dvorchik BH. Studies on the disposition of antipyrine and phenacetin using plasma, saliva and urine. Clin Pharmacol Ther 1975; 18: 259-272.
121. Van Boxtel CJ, Wilson JF, Lindgren S, Sjoqvist F. Comparison of the half-life of antipyrine in plasma whole blood and saliva of man. Eur J Clin Pharmacol 1976; 9: 327-332.
122. Durand DV, Piolat C, Soucheleau J, Baltassat P, Brazier JL. Pharmacocinetique de l'antipyrine. Therapie 1988; 43: 262-266.
123. Idowu OR, Caddy B. A review of the use of saliva in the forensic detection of drugs and other chemicals. J Forensic Sci 1982; 22: 123-135.
124. Cook CE, Tallent CR, Amerson EW, Myres MW, Kapler JA, Taylor GF, Dix Christensen H. Caffeine in plasma and saliva by a radioimmunoassay procedure. J Pharmacol Exp Ther 1976; 199: 679-686.
125. Homing MG, Brown L, Mowlin J, Lertratanangkoon K, Kellanay P, Zion TE. Use of saliva in therapeutic drug monitoring. Clin Chem 1977; 23: 157-164.
126. Scott NR, Chakraborty J, Marks V. Determination of caffeine, theophylline, and theobromine in serum and saliva using high-performance liquid chromatography. Ann Clin Biochem 1984; 21: 120-124.
127. WSahlander A, Mohr S, Paumgartner G. Assessment of hepatic function: comparison of caffeine clearance in serum and saliva during the day and at night. J Hepatol 1990; 10: 129-137.
128. Zylber-Katz E, Grant L, Levy M. Relationship between caffeine concentrations in plasma and saliva. Clin Pharmacol Ther 1984; 36: 133-137.
129. MacKichan JJ, Duffner PK, Cohen ME. Salivary concentration and plasma protein binding of carbamazepine-10, 11-epoxide in epileptic patients. Br J Clin Pharmacol 1981; 12: 31-37.
130. Knott Ch, Reynolds F. The place of saliva in antiepileptic drug monitoring. Ther Drug Monit 1984; 6: 35-41.
131. Bartels H, Oldings HD, Günther E. Use of saliva in monitoring carbamazepine medication in epileptic children. Eur J Pediatr 1977; 126: 37-44.
132. Lucek R, Dixon R. Chlordiazepoxide concentrations in saliva and plasma measured by radioimmunoassay. Res Commun Chem Pathol Pharmacol 1980; 27: 397-400.
133. De Gier JJ, Hart BJ, Wilderink PF, Nelemans FA. Comparison of plasma and saliva levels of diazepam. J Clin Pharmacol 1980; 10: 151-155.
134. Di Gregorio GJ, Piraino AJ, Ruch E. Diazepam concentrations in parotid saliva, mixed saliva, and plasma. Ciin Phanrir acol Ther 1978; 24: 720-725.
135. Dixon R, Crews T. Diazepam: determination in microsamples of blood plasma and saliva by radioimmunoassay. J Anal Toxicol 1978; 2: 210-213.
136. Huffman DH. Relationship between digoxin concentrations in serum and saliva. Clin Pharmacol Therap 1975; 17: 310-312. 137.
137. Van der Vijgh WJF. Comparison of salivary digoxin concentrations with plasma levels in man. Neth J Med 1975; 18: 269-272.
138. Lazowski J, Lypka A, Borkowski P. The relationship between digoxin concentration in saliva and serum. Pol Med Weekly 1978; 23: 1709-11.
139. Jones AW. Inter- and intraindividual variation in the saliva/blood alcohol ratio during ethanol metabolism in man. Clin Chem 1979; 25: 1394-8.
140. Piredda S, Monaco F. Ethosuximide in tears, saliva and cerebrospinal fluid. Ther Drug Monit 1981; 3: 321-328.
141. Van der Graaff M, Vermeiden NP, Heij P, Boeijinga JK, Breimer DD. Pharmacokinetics of orally administered hexobarbital in plasma and saliva of healthy subjects. Biopharmacol Drug Dispos 1986; 7: 265-272.
142. Boxembaum HG, Berkersky I, Mattaliano V, Kaplan SA. Plasma and salivary concentrations of isoniazid in man: preliminary findings in two slow acetylator subjects. J Pharmacokin Biopharmaceut 1975; 3: 443-456.
143. Sharp ME, Wallace SM, Hindmarsh KW, Peel HW. Monitoring saliva concentrations of methaqualone, codeine, secobarbital, diphenhydramine and diazepam after single oral doses. J Analyt Toxicol 1983; 7: 11-14.
144. Patterson AJ, Ritschel WA, Zeltner D, Kim SA. Methotrexate serum and saliva concentrations in patients. Int J Clin Pharmacol Ther Toxicol 1981; 19: 381-385.
145. Kangas L, Allonen H, Lammintausta R, Salonen M, Pekkarinen A. Pharmacokinetics of nitrazepam in saliva and serum after a single oral dose. Acta Pharmacol Toxicol 1971; 29 Suppl:30-47.
146. Klitgaard NA, Kristensen O. Use of saliva for monitoring therapy in epileptic patients. Eur J Clin Pharmacol 1986; 31: 91-94.
147. Smith M, Whitehead E, O'Sullivan G, Reynolds F. A comparison of serum and saliva paracetamol concentration. Br J Clin Pharmacol 1991; 31: 535-545.
148. Glynn JP, Bastian W. Salivary excretion of paracetamol in man. J Pharm Pharmacol 1973; 20: 71-76.
149. Ritschel WA, Tompson GA. Monitoring of drug concentrations in saliva: a non-invasive pharmacokinetic procedure. Meth Find Exptl Clin Pharmacol 1983; 5: 511-525.
150. Schmidt D, Kupferberg HJ. Diphenylhydantoin, phenobarbital and primidone in saliva, plasma? and cerebrospinal fluid. Epilepsia 1975; 16: 735-741.
151. Oneyji CO, Ogubona FA, Dixon PAR. Excretion of proguanil in human saliva. J Pharm Pharmacol 1989; 41: 872-873.
152. Gruneisen A, Witgall H. Abhängigkeit der Speichelkonzentration körperfremder Stoffe von der Blutwasserkonzentration an dem Modell von fünf Sulfonamiden. Eur J Clin Pharmacol 1974; 7: 77-79.
153. Johnson GF, Dechtiaruk WA, Solomon HM. Gaschromatographic determination of theophylline in human serum and saliva. Clin Chem 1975; 21: 144-147.
154. Knop HJ, Kalafusz R, Knols AJF, van der Kleijn E. Preliminary report on the saliva/plasma ratio of theophylline after administration of theophylline derivatives in suppositories. Pharm Weekbl 1975; 110: 1297-99.
155. Levy G, Ellis EF, Koysooko R. Indirect plasma theophylline monitoring in asthmatic children by determination of theophylline concentration in saliva. Pediatrics 1974; 53: 873-876.
156. Shah VP, Riegelman SGLC. Determination of theophylline in biological fluids. J Pharma Sei 1974; 63: 1283-5.
157. Wallace SM, Shah VP, Riegelman S. GLC analysis of acetazolamide in blood plasma and saliva following oral administration to normal subjects. J Pharm Sei 1977; 66: 527-530.
158. Jeffrey AA, Turner P. Relationship between plasma and salivary concentration of amitriptyline. Br J Clin Pharmacol 1978; 5: 268-269.
159. Akimoto Y, Nishimura H, Komiya M, Shibata T, Kancko K, Fujii A, Tamura T. Concentrations of ampicillin and cefadroxil in human serum and mixed saliva following a single oral administration of talampicillin and cefadroxil, and relationships between serum and mixed saliva concentrations. Gen Pharmacol 1985; 16: 273-275.
160. Wan SH, Matin SB, Azamoff DL. Kinetics, salivary excretion of amphetamine isomers and effect of urinary pH. Clin Pharmacol Ther 1978; 23: 585-590.
161. Ogubona FA, Lawal A A, Oneyeji. Saliva secretion of chloroquine in man. J Pharm Pharmacol 1986; 38: 535-537.
162. Thompson LK, Yousefnejad D, Kumor K, Sherer M, Cone EJ. Confirmation of cocaine in human saliva after intravenous use. J Anal Toxicol 1987; 11: 36-38.
163. Cordonnier J, van den Heede M, Heyndrickx A. Saliva concentrations of disopyramide cannot substitute the drug's plasma concentrations. J Anal Toxicol 1987; 11: 179-181.
164. Ducci M, Scalori V, del Tacca M, Soldani G, Bernardini C, Grothe E, Bertelli A. The pharmacokinetics of two erythromycin esters in plasma and in saliva following oral administration in humans. Int J Clin Pharmacol Ther Toxicol 1981; 19: 494-497.
165. Smith RB, Lummis WL, Monovich RE, DeSante KA. Lincomycin serum and saliva concentrations after intramuscular injection in high doses. J Clin Pharmacol 1981; 21: 411-417.
166. Kang GI, Abbott FS. Analysis of methadone and metabolites in biological fluids with gas chromatography-mass spectrometry. J Chromatogr 1982; 231: 311-319.
167. Lynn RK, Olsen GD, Leger RM, Gordon WP, Smith RG, Gerber N. The secretion of methadone and its major metabolite in the gastric juice of humans: comparison with blood and salivary concentrations. Drug Metab Dispos 1976; 4: 504-509.
168. Maronde RF, Wan SH. Antihypertensive effect of metoprolol. In: Onesi G, Klimt CR, editors. Hypertension, determinants, complications, and intervention: Fifth Hahnemann Int Symp Hypertension, Grune and Stratton, New York 1979: 275-279.
169. Virtanen R. Excretion of nortriptyline into saliva. Int J Clin Pharmacol Ther Toxicol 1980; 18: 259-272.
170. Bender IB, Pressman RS, Tashman SG. Studies on excretion of antibiotics in human saliva. Penicillin and streptomycin. J Am Dent Ass 1953; 46: 164-170.
171. Tokugawa K, Ueda K, Fuijto H, Kurakawa T. Correlation between the saliva and free serum concentrations of phenobarbital in epileptic children. Eur J Pediatr 1986; 145: 401-402.
172. Tucker GT, Mather LE. Clinical pharmacokinetics of local anaesthetics. Clin Pharmacokin 1979; 4: 241-278.
173. Galeazzi RL, Benet LZ, Sheiner LB. Relationship between the pharmacokinetics and pharmacodynamics of procainamide. Clin Pharmacol Ther 1976; 20: 278-289.
174. Vermeij P, Van Zwieten PA. Monitoring of free plasma propranolol. Pharm Weekbl Sei Ed 1979; 1: 705-711.
175. Graham G, Rowland M. Application of salivary salicylate data to biopharmaceutical studies of salicylates. J Pharm Sei 1972; 61: 1219-22.
176. Levy G, Procknal JA, Olufs B A, Pachman LM. Relationship between saliva salicylate concentration and free or total salicylate concentration in serum of children with juvenile rheumatoid arthritis. Clin Pharmacol Ther 1980; 619-27.
177. Perez-Mateo M, Erill S, Cabezas R. Blood and saliva salicylate measurements in the monitoring of salicylate therapy. Int J Clin Pharmacol 1977; 15: 113-115.
178. Eatman FB, Maggio AC, Pocelinko R, Boxenbaum HG, Geitner A, Glover W, et al. Blood and salivary concentrations of sulfamethoxazole and trimethoprim in man. J Pharmacokin Biopharmaceut 1977; 5: 615-624.
179. Bonati M, Kanto J, Tognoni G. Clinical pharmacokinetics of cerebrospinal fluid. Clin Pharmacokinet 1982; 7: 312-335.